Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression

Genes and Cancer

Volumn 3, Issue 9-10, 2012, Pages 599-603

  Papa, Antonella ^a,b   Cordon Cardo, Carlos ^a,c   Bernardi, Rosa ^a,b,d   Pandolfi, Pier Paolo ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

angiosarcoma; p53; Pml

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53;

ALLELE; ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HAPLOINSUFFICIENCY; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; IN VIVO STUDY; LYMPHOMA; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; P53 GENE; PML GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 84875526812     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473604     Document Type: Article

References (18)

1. Bernardi R,Pandolfi PP.Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.Nat Rev Mol Cell Biol. 2007;8 (12): 1006-16.
2. Bernardi R,Papa A,Pandolfi PP.Regulation of apoptosis by PML and the PML-NBs.Oncogene. 2008;27 (48): 6299-312.
3. Gurrieri C,Capodieci P,Bernardi R, et al.Loss of the tumor suppressor PML in human cancers of multiple histologic origins.J Natl Cancer Inst. 2004;96 (4): 269-79.
4. Wang ZG,Delva L,Gaboli M, et al.Role of PML in cell growth and the retinoic acid pathway.Science. 1998;279 (5356): 1547-51.
5. Trotman LC,Alimonti A,Scaglioni PP,Koutcher JA,Cordon-Cardo C,Pandolfi PP.Identification of a tumour suppressor network opposing nuclear Akt function.Nature. 2006;441 (7092): 523-7.
6. Bernardi R,Guernah I,Jin D, et al.PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.Nature. 2006;442 (7104): 779-85.
7. Bernardi R,Papa A,Egia A, et al.Pml represses tumour progression through inhibition of mTOR.EMBO Mol Med. 2011;3 (5): 249-57.
8. Jacks T,Remington L,Williams BO, et al.Tumor spectrum analysis in p53-mutant mice.Curr Biol. 1994;4 (1): 1-7.
9. Donehower LA,Harvey M,Slagle BL, et al.Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.Nature. 1992;356 (6366): 215-21.
10. Pearson M,Carbone R,Sebastiani C, et al.PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.Nature. 2000;406 (6792): 207-10.
11. de Stanchina E,Querido E,Narita M, et al.PML is a direct p53 target that modulates p53 effector functions.Mol Cell. 2004;13 (4): 523-35.
12. Guo A,Salomoni P,Luo J, et al.The function of PML in p53-dependent apoptosis.Nat Cell Biol. 2000;2 (10): 730-6.
13. Ferbeyre G,de Stanchina E,Querido E,Baptiste N,Prives C,Lowe SW.PML is induced by oncogenic ras and promotes premature senescence.Genes Dev. 2000;14 (16): 2015-27.
14. Louria-Hayon I,Grossman T,Sionov RV,Alsheich O,Pandolfi PP,Haupt Y.The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.J Biol Chem. 2003;278 (35): 33134-41.
15. Alsheich-Bartok O,Haupt S,Alkalay-Snir I,Saito S,Appella E,Haupt Y.PML enhances the regulation of p53 by CK1 in response to DNA damage.Oncogene. 2008;27 (26): 3653-61.
16. Bernardi R,Scaglioni PP,Bergmann S,Horn HF,Vousden KH,Pandolfi PP.PML regulates p53 stability by sequestering Mdm2 to the nucleolus.Nat Cell Biol. 2004;6 (7): 665-72.
17. Cadwell C,Zambetti GP.The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.Gene. 2001;277 (1-2): 15-30.
18. Berger AH,Knudson AG,Pandolfi PP.A continuum model for tumour suppression.Nature. 2011;476 (7359): 163-9.